Stealth BioTherapeutics Joins the Rare Disease Company Coalition

BOSTON, July 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO). 

The Coalition will engage with policy stakeholders to advocate for impactful drug and healthcare policies and regulations currently under discussion, including prescription drug pricing, to highlight the consequences that blanket legislation can have on continued innovation for rare disease treatments.

Stealth BioTherapeutics Joins the Rare Disease Company Coalition